Cardiac Biomarkers Market to Hit $44.6B by 2030, Growing at 13.4%

NEW YORK - Feb. 21, 2025 - PRLog -- The global cardiac biomarkers market is experiencing significant growth, with a valuation of USD 20.8 billion in 2024 and an anticipated surge to USD 44.6 billion by 2030, reflecting a robust CAGR of 13.4% during the forecast period.

This expansion is primarily driven by the increasing prevalence of acute coronary syndromes (ACS), which continue to pose challenges to healthcare systems worldwide. Technological advancements, particularly in high-sensitivity troponin assays, have enhanced early detection and risk stratification, thereby reducing diagnostic uncertainties. Additionally, the growing adoption of point-of-care testing kits facilitates rapid clinical decision-making in emergency situations, leading to improved patient outcomes. The aging global population, which is more susceptible to cardiac ailments, further propels the demand for advanced diagnostic solutions. Moreover, heightened awareness among healthcare professionals and patients about the importance of early diagnosis contributes to market growth.

Key Insights

Segmentation Analysis

By Type

The market encompasses various biomarkers, including troponins, myocardial muscle creatine kinase, myoglobin, B-type natriuretic peptides (BNPs), ischemia-modified albumin (IMA), and alanine transaminase/aspartate transaminase (ALT/AST).

By Application

Myocardial infarction stands as the largest application category, underscoring the critical role of biomarkers in diagnosing heart attacks. Other applications include congestive heart failure and atherosclerosis.

By Testing Location

Testing is conducted in both laboratory settings and point-of-care locations, with the latter gaining traction due to the need for immediate results in critical care scenarios.

Regional and Geographical Trends

North America

Holds the largest market share, attributed to advanced healthcare infrastructure, high awareness levels, and substantial investments in research and development.

Asia-Pacific

Identified as the fastest-growing region, driven by a rising incidence of cardiac diseases, improving healthcare facilities, and increased healthcare expenditure.

Browse detailed report analysis on "Cardiac Biomarkers Market Growth and Forecast Report, 2030 (https://www.psmarketresearch.com/market-analysis/cardiac-...)"

Competitive Dynamics, Major Players, and Emerging Opportunities

The market is consolidated, with key players focusing on strategic developments such as mergers, acquisitions, and collaborations to strengthen their market position.

Continuous investment in research and development fosters innovation, leading to the introduction of novel biomarkers and testing methodologies.

Emerging opportunities are evident in the development of highly specific and sensitive biomarker assays, catering to the growing demand for precise diagnostic tools.

The increasing shift towards personalized medicine presents avenues for tailored biomarker applications, aligning with individual patient profiles.